Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report

Flavio Giannelli, Ilaria Chiola, Liliana Belgioia, Stefania Garelli, Alice Pastorino, Michela Marcenaro, Serafina Mammoliti, Sergio Costantini, Nicolò Bizzarri, Valerio Vellone, Salvina Barra, Renzo Corvò

Research output: Contribution to journalArticle


Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 – PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.

Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalJournal of Contemporary Brachytherapy
Issue number6
Publication statusPublished - Jan 1 2017



  • High-dose-rate (HDR) brachytherapy
  • Image-guide radiotherapy (IGRT)
  • Vulvo-vaginal hidradenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this